Stefan Frohling
Overview
Explore the profile of Stefan Frohling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
272
Citations
12895
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes
Tremmel R, Hubschmann D, Schaeffeler E, Pirmann S, Frohling S, Schwab M
Pharmacol Rev
. 2025 Feb;
77(1):100014.
PMID: 39952686
Precision cancer medicine is widely established, and numerous molecularly targeted drugs for various tumor entities are approved or are in development. Personalized pharmacotherapy in oncology has so far been based...
2.
Lutz R, Poos A, Sole-Boldo L, John L, Wagner J, Prokoph N, et al.
Sci Immunol
. 2025 Feb;
10(104):eadp6667.
PMID: 39919199
The bone marrow microenvironment plays a crucial role in the development of multiple myeloma. As the disease progresses, malignant myeloma cells can evolve to survive outside the bone marrow. However,...
3.
Behjati S, Boehm J, Dun M, Frohling S, Huang P, Jabado N, et al.
Trends Cancer
. 2025 Jan;
11(2):75-80.
PMID: 39875305
No abstract available.
4.
Unger M, Loeffler C, Zigutyte L, Sainath S, Lenz T, Vibert J, et al.
bioRxiv
. 2025 Jan;
PMID: 39829845
Background: Genomic data is essential for clinical decision-making in precision oncology. Bioinformatic algorithms are widely used to analyze next-generation sequencing (NGS) data, but they face two major challenges. First, these...
5.
Arndt V, Doege D, Frohling S, Albers P, Algul H, Bargou R, et al.
J Cancer Res Clin Oncol
. 2025 Jan;
151(1):39.
PMID: 39825921
No abstract available.
6.
Haggenmuller S, Wies C, Abels J, Winterstein J, Heinlein L, Nogueira Garcia C, et al.
Nat Commun
. 2025 Jan;
16(1):789.
PMID: 39824857
Accurate melanoma diagnosis is crucial for patient outcomes and reliability of AI diagnostic tools. We assess interrater variability among eight expert pathologists reviewing histopathological images and clinical metadata of 792...
7.
Kerle I, Gross T, Kogler A, Arnold J, Werner M, Eckardt J, et al.
NPJ Precis Oncol
. 2025 Jan;
9(1):9.
PMID: 39794422
Precision oncology offers new cancer treatment options, yet sequencing methods vary in type and scope. In this study, we compared whole-exome/whole-genome (WES/WGS) and transcriptome sequencing (TS) with broad panel sequencing...
8.
Marme F, Krieghoff-Henning E, Kiehl L, Wies C, Hauke J, Hahnen E, et al.
Eur J Cancer
. 2025 Jan;
216:115199.
PMID: 39742559
Purpose: Ovarian cancer patients with a Homologous Recombination Deficiency (HRD) often benefit from polyadenosine diphosphate-ribose polymerase (PARP) inhibitor maintenance therapy after response to platinum-based chemotherapy. HR status is currently analyzed...
9.
Nichetti F, Silvestri M, Agnelli L, Franza A, Pircher C, Rota S, et al.
Cancer Med
. 2024 Dec;
13(23):e70393.
PMID: 39618336
Background: The identification of actionable molecular targets of pancreatic cancer (PAC) is key to improving patient outcomes. We hypothesized O6-methylguanine-DNA methyltransferase (MGMT) silencing may occur in a subset of PAC...
10.
Ball C, Frohling S
Cell Stem Cell
. 2024 Oct;
31(10):1389-1390.
PMID: 39366358
Drug sensitivity profiling in patient-derived tumor models offers new hope for improving outcomes in cancers lacking effective therapies. Al Shihabi et al. demonstrate that short-term cultures from bone and soft...